Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection

Marcelo J Wolff; Mónica L Acevedo; María Antonieta Núñez; Mónica Lafourcade; Aracelly Gaete-Argel; Ricardo Soto-Rifo; Fernando Valiente-Echeverría

doi:10.1093/jtm/taac010

Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection

J Travel Med. 2022 May 31;29(3):taac010. doi: 10.1093/jtm/taac010.

Authors

Marcelo J Wolff^{1

2}, Mónica L Acevedo³, María Antonieta Núñez¹, Mónica Lafourcade¹, Aracelly Gaete-Argel³, Ricardo Soto-Rifo³, Fernando Valiente-Echeverría³

Affiliations

¹ Clínica Santa María, Santiago 8389100, Chile.
² Departamento de Medicina Campo Centro, Facultad de Medicina, Universidad de Chile, Santiago 8389100, Chile.
³ Laboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago 8389100, Chile.

Abstract

We report neutralizing antibody titers (NAbTs) elicited by CoronaVac and BNT162b2 vaccines in healthcare workers with and without prior SARS-CoV-2 infection using both a pseudotype-based assay and a commercial kit. NAbTs were higher for the mRNA vaccine and increased in all previously infected. Good correlation between both assays was found.

Keywords: BNT162b2; COVID-19: vaccination; CoronaVac; SARS-CoV-2; anti-RBD kit.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Neutralizing
Antibodies, Viral
BNT162 Vaccine
COVID-19 Vaccines
COVID-19* / prevention & control
Health Personnel
Humans
SARS-CoV-2
Vaccines*

Substances

Antibodies, Neutralizing
Antibodies, Viral
COVID-19 Vaccines
Vaccines
BNT162 Vaccine